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Abstract
The emergence of gene therapies challenge health economists to evaluate interventions that are often provided to a 
small patient population with a specific gene mutation in a single dose with high upfront costs and uncertain long-term 
benefits. The objective of this study was to illustrate the methodological challenges of evaluating gene therapies and 
their implications by discussing four economic evaluations of voretigene neparvovec (VN) for the treatment of RPE65-
mediated inherited retinal disease. The checklist for economic evaluations of gene therapies of Drummond et al. was 
applied to the economic evaluations of VN performed by US Institute for Clinical and Economic Review, two country 
adaptations of the company model in the UK and the Netherlands, and another US publication. The main differences in 
methodological choices and their impact on cost-effectiveness results were assessed and further explored with sensitivity 
analyses using the Dutch model. To enable comparison between the economic evaluations, costs were converted to US 
dollars. Different methodological choices were made in the economic evaluations of VN resulting in large differences 
in the incremental cost-effectiveness ratio varying from US$79,618 to US$643,813 per QALY. The chosen duration 
of treatment effect, source of utility values, discount rate and model structure had the largest impact on the cost-effec-
tiveness. This study underlines the findings from Drummond et al. that standard methods can be used to evaluate gene 
therapies. However, given uncertainty about (particularly long-term) outcomes of gene therapies, guidance is required 
on the acceptable extrapolation of treatment effect of gene therapies and on how to handle the uncertainty around this 
extrapolation in scenario and sensitivity analyses to aid health technology assessment research and align submissions 
of future gene therapies.
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1 Introduction
Gene therapies have long been a promise, potentially bring-
ing durable or even curative clinical benefit. Recently, 
several therapies have started delivering on this promise, 
although long-term effectiveness remains unclear [1]. Cur-
rently available gene therapies are targeted to small patient 
populations with a specific gene mutation and provided in 
one single dose with high upfront costs, while the benefits 
theoretically should last a long time (sometimes even a life-
time). These characteristics have led to a discussion among 
health economists about whether a specific methodological 
reference case is required for economic evaluation of gene 
therapies [2]. Drummond et al. argued that a new meth-
odological reference case for economic evaluation of gene 
therapies is not required because their characteristics are not 
unique to gene therapies [2]. However, they emphasized that 
“the confluence of various characteristics can lead to specific 
methodological challenges when evaluating the cost-effec-
tiveness of a gene therapy” [2]. Therefore, they proposed 
a checklist for economic evaluations of gene therapies to 
inform audiences whether and to what extent key elements 
affecting gene therapies have been identified and considered 
in the analyses [2].
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Key Points 
Different methodological choices were made in the 
economic evaluations of a specific gene therapy (i.e. 
voretigene neparvovec) resulting in large differences in 
cost-effectiveness results.
Standard economic evaluation methods can be used to 
evaluate gene therapies.
Given uncertainty about (particularly long-term) out-
comes of gene therapies, guidance is required on the 
acceptable extrapolation of treatment effect of gene 
therapies and on how to handle the uncertainty around 
this extrapolation in scenario and sensitivity analyses 
to aid health technology assessment research and align 
submissions of future gene therapies.
to the ‘National Institute for Care and Health Excellence’ 
[NICE] in the United Kingdom) will also be reviewed in 
this study [9–11]. Using the list price of VN, the ICER in 
the UK HTA submission from an NHS perspective was 
£86,635/QALY (US$115,513/QALY) and in the Dutch 
HTA submission the ICER from a societal perspective 
was €80,994/QALY (US$95,625/QALY). Finally, an eco-
nomic evaluation applying a similar model as the com-
pany model to the United States’ setting by Johnson et al. 
(2019) was included in this study [12]. Johnson and col-
leagues’ results were vastly different from the US Institute 
for Clinical and Economic Review results; they found an 
ICER of US$79,618/QALY when applying a healthcare 
payer perspective. These examples show that there can 
be substantial differences in the outcomes of economic 
evaluations of the same gene therapy.
In the following, Drummonds’ checklist for assessing 
gene therapies will be applied to the four economic evalua-
tions of VN discussed above [2]. Subsequently, the impact 
of methodological choices on cost-effectiveness outcomes 
will be explored. Finally, the necessity of special methods 
to assess the cost effectiveness of gene therapies will be 
discussed.
2  Methods
Four economic evaluations of VN were evaluated per-
formed by US Institute for Clinical and Economic Review 
[7, 8], the HTA submission to NICE in the UK [9, 10], 
the HTA submission to ZIN in the Netherlands [11] and 
Johnson et al. [12]. The HTA submissions in the UK and 
the Netherlands both used the company model but made 
different methodological choices and are therefore reviewed 
separately. The cost-effectiveness model developed by US 
Institute for Clinical and Economic Review, the company 
model (used in the submission in the UK and the Neth-
erlands) and the model used in Johnson et al. had com-
parable settings. All models used a lifetime time horizon, 
cycle length of 1 year and starting age of 15 in the base 
case. However, the US Institute for Clinical and Economic 
Review model structure differed from the company and 
Johnson et al. model. The US Institute for Clinical and 
Economic Review model used two health states (alive and 
dead). Within the alive state, visual acuity (VA, the ability 
of the eyes to discriminate detail or ‘clarity of vision’) and 
visual field (VF, the total area in which objects can be seen 
while focusing the eyes on a central point) were modelled 
using an exponential and linear functional form, respec-
tively. Efficacy of VN was based on the change in VA and 
VF observed in the clinical trial and extrapolated over 10 
years followed by a 10-year waning period (Table 1) [5]. In 
contrast, the company and Johnson et al. models used VA 
The objective of this study was to illustrate the meth-
odological challenges when evaluating a gene therapy 
and the implications on cost-effectiveness results by dis-
cussing the most recent gene therapy for which economic 
evaluations have been conducted: voretigene neparvovec 
(VN) for the treatment of RPE65-mediated inherited reti-
nal dystrophy (IRD). VN (brand name Luxturna) is one 
of the first gene therapies approved by the US Food and 
Drug Administration (FDA) and the European Medicines 
Agency (EMA) (in 2017 and 2018, respectively) [3, 4]. 
VN is an adeno-associated viral vector-based gene ther-
apy for the treatment of patients with vision loss due to 
IRD caused by mutations in the RPE65 gene [3, 5, 6]. 
During a surgical procedure called vitrectomy, a healthy 
copy of the defective RPE65 gene is introduced into the 
RPE cells in the retina. The healthy copy of the gene 
enables patients to produce functional RPE65 protein, 
which may prevent further deterioration of the patient’s 
visual abilities that would eventually lead to blindness in 
untreated patients. Four of the first economic evaluations 
of VN were selected for review in this study. First, the 
economic evaluation of the US Institute for Clinical and 
Economic Review [7, 8], who were the first to evaluate the 
cost effectiveness of VN compared with best supportive 
care. They reported an incremental cost-effectiveness ratio 
(ICER) of US$643,813 per QALY from the US health 
care system perspective [7]. Since then, the marketing 
authorization holder of VN has submitted health technol-
ogy assessment (HTA) dossiers to national HTA agencies 
in several countries using a commissioned model (from 
now on referred to as the ‘company model’). Two of the 
first HTA submissions of VN submitted in 2019 (to the 
‘Zorginsitituut Nederland’ [ZIN] in the Netherlands and 
Challenges of Evaluating a Gene Therapy for RPE65-Mediated Inherited Retinal Disease
and VF observed in the clinical trial to populate a Markov 
model with five health states (Fig. 1). The extrapolation 
of the treatment effect observed in the clinical trial var-
ied between 20 and 70 years in these economic evaluations 
(Table 1). Furthermore, different list prices, assumptions 
for the duration and waning of treatment effect and sources 
for utilities were used in the four economic evaluations. The 
model characteristics and settings of the four studies are 
summarized in Table 1. Full descriptions of the economic 
evaluations are provided elsewhere [7–9, 11, 12]. The HTA 
submissions in the UK and the Netherlands were sponsored 
by Novartis Pharma and the study of Johnson et al. was 
sponsored by Spark Therapeutics, the economic evaluation 
of US Institute for Clinical and Economic Review did not 
have external sponsors. 
2.1  Drummond’s Checklist
The checklist for assessing the cost-effectiveness of gene 
therapies of Drummond et al. consists of three sections 
related to clinical effectiveness, elements of value and other 
considerations, respectively [2]. For every checklist item, 
the approach in the four economic evaluations of VN was 
described (Table 2).
2.2  Sensitivity and Scenario Analyses
To illustrate the impact of some methodological choices, 
additional analyses were performed using the Dutch adapta-
tion of the company model performed for the HTA submis-
sion to ZIN (from now on referred to as the ‘Dutch model’; 
a technical report of this model is available from the corre-
sponding author upon request). These results are expressed 
in 2018 Euros.
2.3  Comparison of Cost‑Effectiveness Results
To enable comparison between the results of the four eco-
nomic evaluations, costs of the base-case ICER from a 
healthcare and societal perspective were converted to US 
dollars using the 2018 exchange rates [13].
3  Results
Table 2 shows the completed checklist for assessing gene 
therapies [2] for the four economic evaluations performed 
for VN. Individual items that varied between the four eco-
nomic evaluations or required more explanation than pro-
vided in Table 2 are discussed in more detail below.
3.1  Drummond’s Checklist
3.1.1  Clinical Effectiveness
3.1.1.1 Surrogate Endpoint Used The primary outcome in 
the phase III randomized controlled trial (RCT) was change 
in performance on a standardized multi-luminance mobility 
test (MLMT) at 1 year relative to baseline [5]. The MLMT 
quantifies the patient’s ability to navigate around a course 
of obstacles in varying environmental illuminations, includ-
ing very low light levels, integrating aspects of VA, VF and 
light sensitivity [5]. Preferably, the model structure would 
be based on this primary outcome. However, due to the 
absence of data linking the MLMT to costs and utilities and 
long-term data on changes in MLMT, the health states in 
all four models were defined using VA and VF instead of 
MLMT. VA and VF were considered to be the best available 
alternative to MLMT, considering that MLMT is a func-
tional endpoint that also captures changes in VA and VF 
[14, 15].
3.1.1.2 Rare Disease One of the characteristics of gene 
therapies that lead to methodological challenges in eco-
nomic evaluations is that they often target rare condi-
tions [2]. This not only raises challenges in the assess-
ment of clinical effectiveness and safety (discussed later 
in Sect.  3.1.1.5), but also in collecting patient-reported 
health-related quality of life (HRQoL) data. Due to the 
rarity of RPE65-mediated IRD, patient-reported data of 
HRQoL in the target population of VN was not available 
and the feasibility of collecting this data outside the clini-
cal trial setting was limited. As a consequence, alternative 
sources were explored in the four economic evaluations. 
Utilities in the US Institute for Clinical and Economic 
Review model were based on direct utility assessment 
in other retinal disease populations published by Brown 
et al. [16, 17], while the other three economic evaluations 
used utilities derived from clinical experts who completed 
EQ-5D-5L (Johnson et al. and Dutch HTA submission) or 
HUI-3 (health utility index, UK HTA submission) from 
the perspective of patients described in vignettes (Fig. 2) 
[18]. Both sources have limitations: the utility values in the 
US Institute for Clinical and Economic Review study were 
derived from a time trade-off (TTO) exercise in patients of 
a population that was not representative for patients with 
RPE65-mediated IRD (i.e. diabetic retinopathy patients, 
who are older and have diabetes-related comorbidities), 
while the utility values in the other three economic evalu-
ations were based on proxy utility assessment by six US 
clinical experts. Figure 2 illustrates the range in utility val-
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ues for the different sources. The utility values used in the 
US Institute for Clinical and Economic Review model with 
one health state with varying visual impairment based on 
an exponential function were translated to the five health 
states used in the other models. The range in utility values 
between the best and worst health state is smaller in the 
US Institute for Clinical and Economic Review economic 
evaluation than in the other economic evaluations (Fig. 2), 
leading to smaller potential health gains and explaining 
the relatively high ICERs. Application of the utility source 
used in the US Institute for Clinical and Economic Review 
model in the Dutch model resulted in a 58% higher ICER 
(Table 3). 
In the vignette study [18], HRQoL was measured with 
two questionnaires: HUI-3 and EQ-5D-5L. Use of the EQ-
5D-5L for utilities is requested by health economic guide-
lines in the Netherlands and was chosen as the base case in 
Johnson et al. and the Dutch HTA submission. However, 
in contrast to the EQ-5D-5L, the HUI-3 does include a 
vision component. The HUI-3 showed better performance 
in patients with vision disorders than EQ-5D-3L, and the 
majority of studies on the convergent validity of the HUI-3 
with clinical measures demonstrated good validity [19, 20]. 
The company base case in the UK HTA submission therefore 
used utility values based on the HUI-3. The impact of using 
EQ-5D-5L instead of the HUI-3 utilities from the vignette 
study is shown by Viriato et al. [21], who performed com-
parable analyses with the company model for the UK set-
ting, as in the NICE submission, resulting in an ICER of 
£95,072/QALY (compared with £86,635/QALY calculated 
with the HUI-3 in the NICE submission). The UK ICER 
was higher in the NICE submission due to larger utility dec-
rements for HS2 compared with HS1 (the most important 
transition according to the one-way sensitivity analyses [21] 
is from HS1 to HS2) when using the HUI-3 (− 0.16, Fig. 2) 
compared with the UK EQ-5D-5L (− 0.09, Fig. 2). In con-
trast, the Dutch ICER was higher if utility values were based 
on the Dutch EQ-5D-5L tariff compared with the HUI-3 
(Table 3) because of the smaller range in utility values of 
HS1 to HS5 when using the HUI-3 (0.56) instead of the 
Dutch EQ-5D-5L (0.60). Both NICE and ZIN considered 
the lack of patient-reported utility values for patients treated 
with VN to be a key limitation of the cost-effectiveness 
model [9, 11]. As utility values were not captured in the 
clinical trial, only arguments, not data, were available to 
identify an alternative source of utility values. The different 
researchers made different choices based on different argu-
ments and these choices vastly impacted the ICERs.
3.1.1.3 Single‑Arm Trial Often the effectiveness of gene 
therapies is based on single-arm trials. However, in the case 
of VN, a RCT was executed [5]. All four economic evalua-
tions based the clinical efficacy of VN on this RCT. There-
fore, the limitations of single-arm trials do not play a role in 
these economic evaluations.
3.1.1.4 Reporting of Adverse Consequences and Risks John-
son et al. did not include any adverse events because they 
considered that VN was well tolerated and adverse events 
were mostly mild to moderate in severity [12]. The other 
models used the RCT for the incidence of short-term adverse 
events after treatment with VN, but applied different inclu-
sion criteria resulting in different adverse events considered 
in the economic evaluations. However, it is not likely that 
this explains large differences in the cost-effectiveness out-
comes, due to the low healthcare costs and small impact on 
HRQoL of the adverse events. In fact, in a scenario analy-
ses where short-term adverse events are excluded from the 
Dutch model, the ICER only decreases with 0.2% (Table 3).
The administration procedure of VN (i.e. vitrectomy) is 
associated with a risk of cataract [22]. In the UK and Dutch 
HTA submission, all patients with cataract were assumed to 
undergo cataract surgery. In addition to the short-term risk 
of cataract, cataract is commonly reported within 2 years 
following vitrectomy with the incidence rate varying from 
12.5 to 80% [22]. These cataracts, and subsequent impact 
on utilities and costs, were not included in any of the eco-
nomic evaluations because of lack of long-term data on the 
occurrence of cataracts. However, considering the small 
impact on utility (disutility of 0.14 during 1 month) and 
the relative low costs of cataract surgery (£913 in the UK, 
€1062 in the Netherlands [9, 23]) compared with the acqui-
sition costs of VN, and that only a proportion of patients 
(12.5–80%) will experience this adverse event, the impact on 
cost-effectiveness results is expected to be small. Other long-
term adverse consequences and risks are unknown due to 
the limited follow-up period of patients and could therefore 
Fig. 1  Structure of the company model [12]. Patients can transition to 
death from every health state. VI visual impairment, CF counting fin-
gers, HM hand motion, LP light perception, NLP no light perception
 S. A. Huygens et al.
not be included in the economic evaluations until data from 
post-authorization safety studies are available.
3.1.1.5 Size of the Trial Although the efficacy of VN in the 
model could be based on an RCT, the rarity of RPE65-medi-
ated IRD resulted in efficacy data that was based on a small 
number of patients (intervention n = 29 including cross-over 
patients; control n = 9) [5]. As a result, there is a lot of uncer-
tainty around the transition probabilities based on this RCT. 
In particular, the number of patients in the control group 
who received BSC is very low. The data from the RCT was 
not used to model the disease progression of BSC patients in 
the US Institute for Clinical and Economic Review model, 
instead they used natural history data [24]. In contrast, the 
other models used the RCT data of the first year to model 
disease progression in BSC patients. However, because this 
data is only used in the first year of patients receiving BSC 
(i.e. after the first year the transition probabilities are based 
on the natural history data in the BSC arm), the influence 
on the cost-effectiveness outcomes is limited. In a scenario 
Table 2  Drummond et al. checklist for assessing gene therapies completed for four economic evaluations of VN
BSC best supportive care, IRD inherited retinal dystrophy, PAS patient access scheme, QALY quality-adjusted life-year, RCT randomized con-
trolled trial, UK United Kingdom, US United States, US ICER United States Institute for Cost-Effectiveness Research, VA visual acuity, VF 
visual field, VN voretigene neparvovec
Item US-ICER [7, 8] Johnson et al. [12] (US) UK [9] The Netherlands [11]
Clinical effectiveness
 Surrogate endpoint used VA and VF (secondary endpoints in phase III clinical trial) instead of multi-luminance mobility test (primary 
endpoint in RCT)
 Rare disease (number of 
eligible patients)
1000–3000 [8] 1000–2000 [12] 86 [9] 45 [11]
 Serious condition Severe visual impairment throughout childhood with deteriorating vision over time resulting in complete blind-
ness by 30–40 years of age
 Single-arm trial RCT with intervention and control arm
 Paediatric population Age in RCT: mean 15, median 11, interquartile range 6–20 years
 Reporting of adverse con-
sequences and risks
Only short-term adverse 
events included
No adverse events 
included
Only short-term adverse 
events included
Only short-term adverse 
events included
 Size of clinical trial Intervention arm n = 29; control arm n = 9
 Length of clinical trial 1-year data used in model; follow-up data until 3–4 years available
 Extrapolation to long-
term outcomes, number 
of years extrapolation 
of treatment effect
10 years, followed by 
10-year waning period 
from full treatment effect 
to natural history (i.e. no 
treatment effect)
Lifetime, i.e. > 70 years 40 years, followed by 
natural history (i.e. no 
treatment effect)
20 years, followed by natural 
history (i.e. no treatment 
effect)
Elements of value
 Severe disease Not considered Considered in cost-per-
QALY threshold
 Value to caregivers Not considered Considered in a scenario 
analysis
 Insurance value Not considered
 Scientific spillovers Not considered
 Lack of alternatives Before the introduction of VN, there were no interventions that alter the natural history of RPE65-mediated IRD. 
Patients were treated with BSC
 Substantial improvement 
in life expectancy




  Different discount rates 
explored
Not varied in scenario 
analysis
Not varied in scenario 
analysis
1.5% and 0% in scenario 
analyses
0%, 1.5% and 5% for costs 





Threshold analysis to esti-
mate the maximum price 
of VN in order to be cost 
effective
Not considered Confidential simple dis-
count PAS
Pay for performance agree-
ment (‘no cure, no pay’) 
considered in a scenario 
analysis
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using the Dutch model where the transition probabilities of 
patients receiving BSC were based on the natural history 
data [24] from baseline instead of after year 1, the ICER 
increased with 3% (Table 3).
The influence of uncertainty in efficacy data on cost-
effectiveness results was also estimated in probabilistic sen-
sitivity analyses (PSA) using the Dutch model. Because of 
the small number of patients included in the RCT, there were 
no data available on transitions in some of the health states. 
To overcome the potential problem of zero observed counts 
in some of the cells of the matrices, a fixed value (referred 
to as ‘prior’) was added to all cells of the transition matrices. 
In the Netherlands, a prior of 1 was applied as recommended 
by Briggs et al. [25], while in the UK submission a prior of 
Fig. 2  Utility values ranging from moderate visual impairment to 
hand motion/no light perception based on different sources (Lloyd 
et al. [18], Brown et al. [17]). The utility values used in the US-ICER 
model with one health state with varying visual impairment based on 
an exponential function were translated to the five health states used 
in the other models. HS health state, HUI health utility index, NICE 
National Institute for Care and Excellence, TTO time trade-off, UK 
United Kingdom, US ICER United States Institute for Cost-Effective-
ness Research, ZIN Zorginstituut Nederland
Table 3  Scenario analyses using Dutch adaptation of company model
BSC best supportive care, ICER incremental cost-effectiveness ratio, NICE National Institute for Health and Care Excellence, QALY quality 





ICER (€) % Change from 
base-case ICER
Base case (according to ‘The Netherlands’ model specification in Table 2) 672,736 8.31 80,994
Utilities
 Utility values: Brown et al. [17] (used in US-ICER) 672,736 5.24 128,368 + 58%
 Utility values: Lloyd et al. [18] HUI-3 values 672,736 7.36 91,445 + 13%
Reporting of adverse consequences and risks
 Exclusion of adverse events 672,551 8.32 80,836 0%
Size of the trial
 BSC effectiveness from natural history data 669,360 7.99 83,779 3%
Extrapolation to long-term outcomes
 Duration of treatment effect: 10 years +10 years waning effect (comparable to 
US-ICER assumptions)
680,045 5.88 115,673 + 43%
 Duration of treatment effect: 40 years (NICE submission assumption) 662,891 12.21 54,310 − 33%
 Duration of treatment effect: 70 years (life-long; Johnson et al. assumption) 658,708 13.94 47,239 − 42%
Value to caregivers
 Include caregiver disutility 672,736 8.52 78,974 − 2%
Improvements in life expectancy
 Include excess mortality risk 672,791 8.27 81,364 0%
Discounting
 4% discount rate for costs and outcomes 672,736 4.60 146,395 + 81%
List price VN US
 List price VN equal to US 702,686 8.31 84,600 + 4%
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0.1 was used. Our results showed that the chosen prior intro-
duced uncertainty. Depending on the prior, the average ICER 
of 10,000 PSA iterations varied from €95,970 with a prior of 
0.1 to €108,752 per QALY gained with a prior of 1 (Fig. 3).
3.1.1.6 Length of  Clinical Trial The efficacy data in the 
health economic model was based on the 1- or 2-year results 
of the RCT in all four economic evaluations [5]. At the time 
of the economic evaluations performed with the company 
model, 3–4 years follow-up data was available for the RCTs 
(Study 301/302) [26]. However, the available data from 
years 2 and 3 was not used as the modelers argued that the 
distribution of patients across health states would be essen-
tially the same as the assumption of stabilization beyond 
year 1 because significant changes in outcomes beyond year 
1 were not observed. In any case, the follow-up period is rel-
atively short for the potential promise of lifetime duration of 
treatment effect of VN. Ideally, longer follow-up data would 
have been included in the model but waiting on additional 
long-term data would postpone the availability of treatment 
for patients for several years. Instead, the results of the trial 
were extrapolated to long-term outcomes.
3.1.1.7 Extrapolation to Long‑Term Outcomes The efficacy 
data was based on the 1-year follow-up of patients in the 
RCT in all four models [5]. Due to the short timeframe of 
the clinical trial, an important part of the value hypothesis of 
VN (i.e. long-term benefit) is not substantiated by trial data 
[27]. However, the current data and biological knowledge 
on the (patho)physiology of the targeted cells supported 
the suggestion of maintained improvement of visual func-
tion after injection with VN beyond what has been observed 
in the RCT. Current available data shows that the major-
ity of patients (86%) included in the RCT showed stable 
functional vision 1 year post-treatment through 3–4 years 
of follow-up [28]. Furthermore, 7.5- and 4-year follow-
up data of the phase I clinical trial for the first and second 
injected eye, respectively, showed sustained improvements 
on full-field light sensitivity threshold (FST) in the major-
ity of the patients [5, 15, 29]. These FST improvements are 
relevant because a post-hoc analysis of the RCT described 
a good correlation between MLMT performance and FST 
[15]. Furthermore, it is anticipated that the RPE65 gene 
will remain active during the lifetime of RPE cells, which 
normally undergo minimal proliferation (i.e. cell division) 
throughout life [21].
The four economic evaluations applied different assump-
tions on the duration of treatment effect. The treatment effect 
in the US Institute for Clinical and Economic Review model 
was assumed to be sustained for 10 years after which they 
modelled a waning period of 10 years in which the effect 
slowly decreased until the rate of decline in vision was the 
same as with BSC [7, 8]. A treatment effect duration of 20 
years was assumed in the Dutch HTA submission. In the 
base-case analysis of the submission to NICE, a 40-year 
treatment effect duration was assumed [9]. Finally, the treat-
ment duration effect was extrapolated to the entire patient’s 
lifetime (i.e. ± 70 years) in Johnson et al. [12]. Scenario 
analyses showed that this parameter has the largest impact 
on the cost-effectiveness outcomes in all four economic 
evaluations. In the US Institute for Clinical and Economic 
Review report, the ICER decreased from US$643,813 to 
US$384,624 per QALY when applying a lifetime duration 
of the treatment effect instead of the 10 years with a 10-year 
waning period [7]. The ICER (without indirect costs) in the 
US economic evaluation of Johnson et al. increased from 
US$79,618 to US$380,185 when the treatment effect was 
assumed to last for only 3 years instead of a lifetime [12]. 
In the UK HTA submission, the ICER increased by 25% if 
a 20-year treatment duration was assumed and decreased 
by 5% if the treatment duration was assumed to be 50 years 
instead of 40 years in the base-case analysis [9]. The impact 
of the assumed treatment duration using the Dutch model is 
illustrated in Fig. 4 (blue line) and Table 3, ranging from an 
Fig. 3  Cost-effectiveness ellip-
ses and mean ICERs with vary-
ing priors. ICER incremental 
cost-effectiveness ratio, QALY 
quality-adjusted life-year
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ICER of €80,994/QALY when a 20-year duration of treat-
ment effect was assumed to €47,239/QALY when a lifetime 
duration of treatment effect was assumed.
3.1.2  Elements of Value
3.1.2.1 Severe Disease Severity of disease is one of the 
additional elements of value beyond the QALY that may 
have the most support in the health economic field, but it has 
not been applied in many countries yet. The US Institute for 
Clinical and Economic Review, UK HTA submission and 
Johnson et al. did not consider the severity of disease in their 
analyses. In the Netherlands, however, the Dutch health eco-
nomic guidelines state that the appropriate cost-per-QALY 
threshold depends on the severity of the disease expressed 
in proportional shortfall [30]. Proportional shortfall refers 
to QALYs lost due to disease as a proportion of quality-
adjusted life expectancy of the age- and gender-matched 
general population. The severity-weighted thresholds are 
20,000, 50,000 and 80,000 euro per QALY for proportional 
shortfalls (proportion of normal quality-adjusted life expec-
tancy lost) under 41%, 71% and 100%, respectively [31]. 
Proportional shortfall is calculated with the iMTA disease 
burden calculator [32]. The proportional shortfall of RPE65-
mediated IRD patients was estimated to be 69% based on 
the mean QALYs in BSC and VN derived from the deter-
ministic analysis using the Dutch model, corresponding 
to a €50,000/QALY threshold. The proportional shortfall 
was also estimated for every PSA iteration using the Dutch 
model. The 95% confidence interval of these proportional 
shortfall estimates was 39–90%, indicating the high uncer-
tainty around the proportional shortfall. Most of the PSA 
iterations (52%) using the Dutch model resulted in a pro-
portional shortfall of 70% or higher corresponding to a cost-
per-QALY threshold of €80,000/QALY. To consider the 
uncertainty around the appropriate cost-per-QALY thresh-
old, the severity-adjusted probability of being cost effective 
(SAPCE) [32] was calculated using the Dutch model. This 
procedure evaluates the ICER against the likelihood of each 
of the three severity-adjusted thresholds. SAPCE was 10%, 
compared with the probability of being cost effective of 0% 
when the ICER was evaluated against a single threshold of 
€50,000 per QALY or 19% when evaluated against a single 
threshold of €80,000/QALY. ZIN concluded that the sever-
ity of disease of RPE65-mediated IRD patients is difficult 
to estimate due to concerns about the validity of the utility 
values and uncertainty around the extrapolation of treatment 
effect of VN but is likely to be high due to the physiological 
impact of the disease [11].
3.1.2.2 Value to  Caregivers The severity of RPE65-medi-
ated IRD, just like many other diseases treated by gene ther-
apy, means that the burden falling on caregivers is high. All 
four economic evaluations included caregiver costs in their 
base-case or scenario analyses, but only the NICE submis-
sion included the value of VN to caregivers on the effect 
side. Exclusion of the carer disutilities in a scenario analysis 
showed that the ICER increases by 9% if carer disutilities 
are not taken into account [9]. The US Institute for Clinical 
and Economic Review report states that VN may improve 
the independence of patients and thus reduce caregiver and 
family burden, but that there is no data available to substan-
tiate this assumption at this time [7]. Besides limited data 
availability, there are methodological challenges to includ-
ing the value to caregivers, such as the uncertainty about the 
proportion of informal caregivers who experience disutil-
ity, unknown number of informal caregivers or other family 
members or friends who experience disutility and unknown 
duration of disutility in the caregivers. In addition to the 
challenges of including disutilities of caregivers, it is debat-
Fig. 4  Cost-effectiveness results 
for varying durations of treat-
ment effect of VN and utility 
sources (Brown et al. [17] and 
Lloyd et al. [18]) using the 
Dutch health economic model. 
HUI health utility index, HS 
health state, ICER incremen-
tal cost-effectiveness ratio, 
NL the Netherlands, QALY 
quality-adjusted life-year, TTO 
time trade-off, VN voretigene 
neparvovec
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able whether the standard cost-per-QALY threshold should 
be applied to outcomes of cost-effectiveness analyses includ-
ing disutilities of caregivers. For example, a threshold based 
on an opportunity cost framework should take into account 
that displaced treatments also generate caregiver utilities.
Despite these challenges, an explorative scenario analysis 
was performed including the impact of carer disutility using 
the Dutch model to provide insight into the potential impact 
of considering the consequences of informal caregiving on 
the effect side. The results of the scenario analysis showed 
that including carer disutility resulted in a 2% lower ICER 
(Table 3).
3.1.2.3 Lack of  Alternatives Before the introduction of 
VN, there were no interventions that could alter the natu-
ral history of RPE65-mediated IRD. Patients were treated 
with best supportive care, which may include correction 
of refractive error (i.e. glasses, contact lenses or refractive 
surgery), low-vision aids (e.g. strong magnifying reading 
glasses and loupes) and optimal access to educational and 
work-related opportunities. The lack of alternative treat-
ment may result in a greater tendency by decision makers to 
accept high ICERs.
3.1.2.4 Substantial Improvements in Life Expectancy In all 
four economic evaluations, the base-case analysis assumed 
that RPE65-mediated IRD does not affect mortality risk and 
therefore treatment with VN does not improve life expec-
tancy. In the company’s base case in the submission to 
NICE, an increased risk of death was modelled based on 
the hazard ratios reported in Christ et al. [33]. However, this 
assumption was not included in the evidence review group’s 
base case because no deaths occurred in any study included 
in VN’s evidence base and the population in Christ et al. (i.e. 
patients aged 65–84 years) was substantially different from 
the target population of VN (i.e. patients aged 15 years at 
baseline) [9]. Including the excess mortality reported by 
Christ et al. (RR of 1.08 in health state 1 and 1.18 in health 
states 2–5) results in an increase of the ICER of 0.5% in the 
Dutch model (Table 3).
3.1.3  Other Considerations
3.1.3.1 Discounting Gene therapies often have large 
upfront costs because the therapy is delivered in a single 
dose, while the benefits stretch far into the future [34]. A 
lower discount rate would therefore be more favourable for 
gene therapies. However, Drummond et al. do not believe 
that deviating from the general methodological principle 
applied in most countries of discounting costs and benefits 
at the same rate is justified when evaluating gene therapies 
[2]. Nevertheless, they recommend that different discount 
rates for costs and benefits should be explored in scenario 
analyses [2]. However, the discount rate was only varied in 
scenario analyses in two of the four economic evaluations 
reviewed in this study: the UK and Dutch HTA submissions. 
NICE stated that discount rates of 1.5% may be appropri-
ate to consider because clinical evidence suggests benefits 
of VN may extend beyond 30 years and VN requires the 
NHS to commit significant, irrecoverable costs as a ‘one-
off’ gene therapy. The ICER in this scenario analysis was 
43% lower than the base-case ICER. ZIN also specifically 
requested additional scenario analyses with other discount 
rates. In the Netherlands, differential discounting for costs 
(4%) and effects (1.5%) is prescribed by the health economic 
guidelines [30]. A scenario analysis using the Dutch model 
in which the discount factor of effects was increased to 4% 
(i.e. equal to costs) showed that the impact of this assump-
tion is substantial, that is, an 81% higher ICER compared 
with using the 1.5% discount rate for effects that is usually 
applied in the Netherlands (Table 3).
3.1.3.2 Uncertainty—Alternative Payment Models Payers 
are faced with the challenge to determine whether to reim-
burse the high one-time costs of VN that potentially, but not 
certainly, result in lifelong benefits. Managed entry agree-
ments (MEA) between manufacturers and payers are a way 
to reduce the uncertainty related to the lack of long-term 
data at launch [27]. MEAs can take the form of discounts or 
be outcome-based (e.g. pay for performance). The US Insti-
tute for Clinical and Economic Review did not investigate 
a formal alternative payment model, but they performed 
threshold analyses to estimate the maximum price of VN 
in order to achieve an ICER that is below certain cost-per-
QALY thresholds that could be used to determine discounts 
for VN. In the NICE submission, confidential simple dis-
count patient access schemes were included [9]. In the Neth-
erlands, ZIN advised to implement a pay-for-performance 
arrangement with the market authorization holder of VN 
(Novartis) as a condition for reimbursement, the details of 
such an agreement have not been disclosed following confi-
dential negotiations between the Dutch Ministry of Health 
and the market authorization holder [11].
3.2  Sensitivity and Scenario Analyses
Table 3 summarizes the sensitivity and scenario analyses 
performed with the ‘Dutch model’ mentioned in the dis-
cussion of the Drummond checklist in paragraph 3.1. The 
assumption of the duration of treatment effect, discount rates 
and utility values had the largest impact on the cost-effec-
tiveness results. As discount rates are prescribed by national 
health economic guidelines, only the duration of treatment 
effect and utility values were considered in two-way sensitiv-
ity analyses using the Dutch model. The results are presented 
in Fig. 4 and Table 4.
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3.3  Comparison of Cost‑Effectiveness Results
Table 5 summarizes the cost-effectiveness results of the 
four economic evaluations converted to 2018 US dollars. 
Due to the relatively short extrapolation of treatment effect, 
the use of utilities from a diabetic retinopathy population 
and the model structure with one health state with varying 
visual impairment, the ICER of US Institute for Clinical 
and Economic Review was the highest of the four economic 
evaluations [7]. In contrast, due to the lifetime extrapola-
tion of treatment effect and the use of utilities based on the 
RPE65-mediated IRD vignette study, Johnson et al. reported 
the lowest ICER of the four studies [12].
Despite the longer duration of treatment effect and use of 
the same utility source as the Dutch HTA submission, the 
ICER of the UK HTA submission was higher than the ICER 
of the Dutch HTA submission from a healthcare perspective. 
This is not only due to the different extrapolation of treat-
ment effect; if a 40-year treatment effect duration is applied 
in the Dutch model with a healthcare perspective, the ICER 
would be even lower (i.e. US$67,371/QALY). This is mainly 
due to the difference in discount rates between the UK and 
the Netherlands. If the discount rates in the Dutch model are 
adjusted to the UK discount rates (i.e. 3.5% for both costs 
and effects), the ICER increases to US$122,784/QALY. If 
the other model settings were also equal to the UK settings 
(including average eye instead of best-seeing eye and no 
use of cross-over data), the ICER in the Dutch model would 
be comparable to the UK ICER (i.e. US$115,077/QALY).
In contrast to the healthcare perspective, the ICER of the 
UK is lower than the ICER of the Netherlands when apply-
ing a societal perspective. This is caused by the inclusion of 
more societal costs in the societal perspective of the UK than 
the Netherlands. In addition to informal care costs, the UK 
included social security benefits and caregiver productivity 
losses. Furthermore, patient productivity losses were esti-
mated with the human capital method, while the friction cost 
method was applied in the Netherlands in which productivity 
losses are only included for a limited period of time (i.e. 3 
months in the Netherlands).
4  Discussion
Four economic evaluations of VN were discussed in this 
paper. Properties of the clinical evidence, such as sample 
size, duration of the clinical trial and the use of surrogate 
outcomes, required a number of assumptions to model long-
term cost-effectiveness. Different reimbursement authorities 
preferred different assumptions and this resulted in large 
differences in the cost-effectiveness estimates, mainly due 
to different assumptions on duration of treatment effect 
of VN, discount rates, sources of utility values and model 
structures. However, the difficulty in translating available 
clinical evidence to long-term cost-effectiveness estimates 
is not unique to gene therapies. Also, the impact of assump-
tions can be assessed with standard methods for sensitivity 
analyses that can also be applied to other types of therapies. 
Therefore, this study underlines the statement of Drummond 
et al. that gene therapies do not require a new methodo-
logical reference case for economic evaluation. However, as 
Angelis et al. rightly expressed, gene therapies are “pushing 
against the boundaries of the methodological and budgetary 
capacity available” [35]. Our study showed that guidelines 
on the acceptable extrapolation of treatment effect of gene 
therapies and on the reporting of results when important 
input parameters are highly uncertain are necessary to aid 
HTA research and align submissions of new gene therapies. 
Table 4  Two-way sensitivity analysis varying duration of treatment effect and utility values
HUI Health Utility Index, TTO time trade-off
Duration of treat-
ment effect, in 
years
Proxy utility assessment using EQ-
5D-5L in same patient population 
(source Lloyd et al. 2019 [18]) (€)
Proxy utility assessment using HUI-3 in 
same patient population (source Lloyd 
et al. 2019 [18]) (€)
Direct utility assessment with TTO in 
different patient population (source 
Brown et al. 1999 [17]) (€)
10 + 10 waning 115,673 131,147 184,417
20 80,994 91,445 128,368
40 54,310 61,002 85,873
70 (± life-long) 47,239 52,628 74,325
Table 5  Incremental cost-effectiveness ratios (ICERs) in 2018 US 
dollars of the four economic evaluations
HTA Health technology assessment, NL The Netherlands, UK United 
Kingdom, US United States, US ICER United States Institute for 






US-ICER report 643,813 480,130
US Johnson et al. 79,618 VN dominant
UK HTA submission 115,513 86,247
NL HTA submission 99,104 95,625
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In addition, alternative payment models, such as MEAs 
between manufacturers and payers, can reduce the financial 
risk of the payer associated with the uncertainty of (cost-) 
effectiveness due to the lack of long-term data at launch.
In the case of VN, uncertainty was mostly related to the 
extrapolation of the treatment effect. According to Gon-
çalves, the willingness to consider economic models that 
include extrapolating longer-term benefit from limited exist-
ing data varies between HTA agencies [27]. In the case of 
VN, both NICE and ZIN did not have objections about the 
extrapolation of treatment effect proposed by the manufac-
turer for the base-case analysis, but in the UK, this was set 
to 40 years, while in the Netherlands a more conservative 
assumption of 20 years was applied. Uncertainty about the 
long-term benefits is not unique to VN but will likely be an 
important question in other gene therapies as well due to 
the unavoidable lack of long-term data supporting lifetime 
benefits at market entry [36]. One may even suggest that 
it is impossible to define a base case based on this limited 
data, but in practice HTA agencies will probably request or 
define the most plausible scenario anyway. Therefore, the 
methodological reference case may not need to be changed 
for this issue, but it does call for guidance on the acceptable 
extrapolation of treatment effect and the required evidence 
base (e.g. duration of trial or expert opinion) to support 
this assumption. Furthermore, the uncertainty around the 
assumed duration of treatment effect can be handled in dif-
ferent ways. In the economic evaluations of VN, the uncer-
tainty around the treatment effect duration assumption was 
addressed by performing extensive scenario analyses assum-
ing different treatment effect durations that can be presented 
in a table or plot (e.g. Fig. 4 in this paper). This is in line 
with the new approach of the US Institute for Clinical and 
Economic Review, who decided to perform ‘optimistic’ and 
‘conservative’ scenario analyses in which the clinical benefit 
is varied in their analyses of high-impact “single and short-
term therapies” [37], and recommendations by Angelis et al. 
[35]. Although these scenario analyses can show the impor-
tance of this assumption on the cost-effectiveness results, it 
is still up to the discretion of the decision maker how this 
uncertainty is weighted in the final reimbursement decision. 
One way to potentially improve the plausibility of the treat-
ment effect duration assumption is to include feedback from 
clinical experts about the expected long-term benefits in a 
formal manner using the Sheffield Elicitation Framework 
(SHELF) [38]; for example, like Cope et al. did for CAR-T 
therapy [39]. Experts could be asked to estimate upper and 
lower plausible limits and then the most likely duration of 
the treatment effect of VN based on their clinical experi-
ence and knowledge, for example. Based on the uncertainty 
around the most likely estimates of the experts provided by 
the upper and lower plausible limits, a probability distribu-
tion of this input parameter could be included in the PSA. 
This way the uncertainty around the treatment effect dura-
tion would be formally included in the cost-effectiveness 
plane and acceptability curve.
Another important issue was the small patient popula-
tion, which, among other things, complicated collecting 
utility values. Utilities in the HTA submissions in the UK 
and the Netherlands as well as Johnson et al. were based on 
a vignette-based study where utilities were estimated based 
on expert valuation of health state descriptions given by 
patients and caregivers [18]. The main critique of this study 
by HTA agencies was that the resulting utilities are based on 
proxy utility assessment [9, 11]. Ideally, utility data should 
have been collected directly from (the parents of) patients 
using a quality-of-life questionnaire (i.e. HUI or EQ-5D-5L) 
during the RCT. The main limitation of a direct valuation 
study would be that it yields data from a small number of 
patients. However, the transition probabilities used in the 
health economic model are also based on this small number 
of patients and the patient-reported utilities could at least 
have been used as validation of the utilities derived by expert 
elicitation. In the specific case of vision problems, additional 
problems arise in using EQ-5D to collect utility data as it 
does not include a vision component [19]. In contrast, the 
HUI-3 does include a vision component and indeed showed 
better performance in patients with vision disorders and the 
majority of studies on the convergent validity of the HUI-3 
demonstrated good validity [19, 20]. Another alternative 
is using a mapping algorithm to convert VA to EQ-5D-3L 
published recently by Pennington et al. [40]. However, an 
important limitation of using this algorithm in the case of 
VN would be that it is only based on VA and not on the pri-
mary outcome of the clinical trial (i.e. MLMT) or any of the 
other important secondary outcomes (i.e. VF and FST). In 
contrast to extrapolation of treatment effect, limited quality 
of available data on HRQoL is not necessarily an issue in 
all gene therapies. Therefore, this issue also does not call for 
changing the methodological reference case for gene thera-
pies. The specific (and often small) patient populations with 
certain gene mutations that gene therapies are often targeted 
to, however, bring the same challenges as with evaluating 
interventions for orphan diseases. Therefore, guidance and 
regulations for rare diseases may also be applicable to gene 
therapies.
Although sensitivity analyses can provide more insight on 
the impact of certain uncertain parameters, the capability of 
these analyses to help deal with the decision uncertainty is 
limited [2]. In practice, MEAs are often arranged to share 
the financial risk between the healthcare payer and the man-
ufacturer [41]. This often entails that funding and use of the 
intervention is restricted to certain centres, and real-world 
patient outcomes must be recorded [42]. Outcomes-based 
arrangements have their limitations, mostly related to the 
difficulty in defining appropriate outcomes and thresholds 
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to define response, and the significant clinical, administra-
tive and patient burden. This has historically limited their 
implementation and favoured confidential discounts instead 
[42]. In the case of VN, however, the patient population is 
limited and durable outcomes that are sensitive to change are 
well defined [15, 43]. The feasibility of such an agreement 
has been shown in the US, where the manufacturer of VN 
(Spark Therapeutics) is offering outcome-based agreements 
that include rebates to payers if established efficacy goals (in 
terms of full-field light sensitivity threshold scores against 
baseline measurements) are not reached at 30–90 days and 
30 months [44].
5  Conclusion
As the first gene therapy is approved by the FDA and EMA 
for retinal diseases, clinicians are gaining their first expe-
riences with gene therapies that may increasingly become 
standard care in the future. At the same time, VN also pro-
vided a valuable learning experience for health economists 
by highlighting the challenges in evaluating the cost effec-
tiveness of gene therapies, which can help in improving the 
economic evaluation of future gene therapies. But in general, 
this study showed that standard methods can be used for the 
economic evaluation of gene therapies, supporting Drum-
mond et al. statement. However, due to uncertainty about the 
(long-term) outcomes of gene therapies, health economists 
evaluating the same intervention can end up making differ-
ent methodological choices resulting in large variations in 
cost-effectiveness results. This study showed that the main 
challenge in evaluating gene therapies is handling the prom-
ise of long-term benefits that are not observed in clinical 
trials yet. This calls for guidance on the acceptable extrapo-
lation of treatment effect of gene therapies in the base-case 
analysis and on how to handle the uncertainty around this 
extrapolation in scenario and sensitivity analyses to aid HTA 
research and align submissions of future gene therapies. As 
a single assumption on extrapolation of treatment effect is 
likely to be incorrect, exploration of the impact of the main 
assumptions that drive model results in a table or figure as 
presented in this paper (Fig. 4) is recommended. In addi-
tion, alternative payment models can reduce the financial 
risk caused by uncertainty of long-term outcomes due to 
lack of long-term data at launch.
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